AstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion

Reuters2026/07/27 06:03

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AstraZeneca reported H1 2026 revenue of USD 30.67 billion, up 9% from a year earlier.
Reported EPS rose 4% to USD 3.60, while core EPS climbed 12% to USD 5.21.
Q2 revenue increased 6% to USD 15.38 billion; reported EPS rose 2% to USD 1.61.
H1 product sales grew 8% to USD 28.9 billion, while alliance revenue jumped 31% to USD 1.7 billion.
Management said it remains on track for its USD 80 billion total revenue ambition for 2030, despite the CARDIO-TTRansform outcome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief via Cision (Ref. ID: 202607270200BITN____UKPR__EN_20260727-BIT-1901-0) on July 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AstraZeneca FY26 H1 reported EPS rises 4% to $3.60; revenue climbs 9% to $30.67 billion

You may also like

Crypto prices